Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

18. august 2020 opdateret af: GlaxoSmithKline

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD

The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

61

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alabama
      • Mobile, Alabama, Forenede Stater, 36608
        • GSK Investigational Site
    • Colorado
      • Wheat Ridge, Colorado, Forenede Stater, 80033
        • GSK Investigational Site
    • Maine
      • Biddeford, Maine, Forenede Stater, 04005
        • GSK Investigational Site
    • Missouri
      • Saint Louis, Missouri, Forenede Stater, 63141
        • GSK Investigational Site
    • New Jersey
      • Summit, New Jersey, Forenede Stater, 07091
        • GSK Investigational Site
    • Oregon
      • Medford, Oregon, Forenede Stater, 97504
        • GSK Investigational Site
    • Pennsylvania
      • Erie, Pennsylvania, Forenede Stater, 16508
        • GSK Investigational Site
    • South Carolina
      • Greenville, South Carolina, Forenede Stater, 29615
        • GSK Investigational Site
      • Spartanburg, South Carolina, Forenede Stater, 29303
        • GSK Investigational Site
    • Tennessee
      • Johnson City, Tennessee, Forenede Stater, 37601
        • GSK Investigational Site
    • Texas
      • San Antonio, Texas, Forenede Stater, 78229
        • GSK Investigational Site
    • Washington
      • Spokane, Washington, Forenede Stater, 99204
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • male and females 40 to 80 years of age (inclusive)
  • COPD diagnosis
  • Current or previous smokers with a cigarette smoking history of at least 10 pack-
  • Post-albuterol FEV1/FVC of 0.70 or less
  • Post-albuterol FEV1 of 35% to 80% (inclusive)

Exclusion Criteria:

  • Pregnant or lactating females
  • current diagnosis of asthma
  • respiratory disorders other than COPD
  • clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine, or hematological abnormalities that are uncontrolled
  • clinically significant sleep apnea
  • previous lung resection surgery
  • clinically significant abnormalities confirmed by chest x-ray that are not related to COPD
  • hospitalization for COPD within 3 months of screening
  • use of antibiotics for lower respiratory tract infection within 6 months of screening
  • abnormal and clinically significant 12-lead ECG findings
  • current malignancy in remission for less that 5 years
  • medical conditions that would contraindicate the use of anticholinergics
  • positive hepatitis B or C test
  • history of alcohol or drug abuse
  • unable to withhold albuterol for 6 or more hours
  • use of long term oxygen therapy
  • conditions that would limit the validity of informed consent
  • use of GW642444 or GSK233705 in previous studies
  • use of an investigation drug with 30 days of screening
  • use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone propionate or equivalent
  • hypersensitivity to beta-agonists
  • concurrent use of long-acting beta-agonists (LABA) or long-acting muscaring antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators, inhaled short acting anticholinergics.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm 1
The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
Placebo komparator: Arm 2
matchende placebo

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Weighted Mean Pulse Rate Over (0-4 Hours) at Day 28.
Tidsramme: Baseline (Pre-dose, Day 1) and Day 28
Baseline was the most recent result taken on or before pre-dose (Day 1). The analysis was performed using a Repeated Measures Model. This model used all available weighted mean pulse rate values recorded. Change from Baseline was calculated as (Change from Baseline = Assessment value - Baseline value).
Baseline (Pre-dose, Day 1) and Day 28

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: On-treatment; from treatment start until one day after treatment stop (Up to Day 29)
AE was defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE include AEs those result in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
On-treatment; from treatment start until one day after treatment stop (Up to Day 29)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

  • GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. november 2008

Primær færdiggørelse (Faktiske)

12. februar 2009

Studieafslutning (Faktiske)

12. februar 2009

Datoer for studieregistrering

Først indsendt

8. september 2008

Først indsendt, der opfyldte QC-kriterier

8. september 2008

Først opslået (Skøn)

9. september 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. september 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. august 2020

Sidst verificeret

1. august 2020

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • DB1111581

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Studiedata/dokumenter

  1. Studieprotokol
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  2. Annoteret sagsbetænkningsformular
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  3. Datasætspecifikation
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  4. Statistisk analyseplan
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  5. Formular til informeret samtykke
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  6. Individuelt deltagerdatasæt
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
  7. Klinisk undersøgelsesrapport
    Informations-id: DB1111581
    Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .